A. Glucose-dependent enhancement of insulin release, reduction of inappropriate glucagon secretion and delayed gastric emptying
Why this is correct
GLP-1 is an incretin secreted primarily from intestinal L cells in response to nutrient intake. GLP-1 receptor agonists enhance glucose-dependent beta-cell insulin secretion, suppress inappropriately elevated glucagon under hyperglycemic conditions, slow gastric emptying for many agents, and increase satiety through gut–brain pathways. Glucose dependence helps explain their relatively low intrinsic hypoglycemia risk when used without insulin or insulin secretagogues. The exact magnitude and persistence of gastric emptying effects vary by agent.
Why each option is correct or incorrect
Correct: GLP-1 receptor agonists coordinate glucose-dependent insulin action, glucagon modulation and satiety-related effects.
KATP channel closure independent of glucose is associated with sulfonylureas, not the characteristic GLP-1 mechanism.
SGLT2 inhibitors cause glycosuria through proximal renal transport blockade.
Excess catecholamine secretion raises rather than lowers glucose and is not the therapeutic incretin effect.
High-yield notes
- GLP-1 is released from intestinal L cells after nutrient exposure.
- GLP-1 receptor agonists increase glucose-dependent insulin secretion.
- Many agents reduce appetite and weight; GI adverse effects are common.
GLP-1 effects are glucose dependent, whereas sulfonylureas can provoke hypoglycemia during fasting.
Not every incretin therapy has identical effects: DPP-4 inhibitors are not pharmacologically identical to GLP-1 receptor agonists.